Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac magnetic resonance imaging in patients referred for premature ventricular contractions: identifying patients most likely to benefit.

Frontiers in cardiovascular medicine·2026
Same author

Concomitant Hypertension in Hypertrophic Cardiomyopathy: Clinical Phenotype and Prognostic Associations of Cardiovascular Magnetic Resonance Biomarkers.

European journal of preventive cardiology·2026
Same author

Prognostic Impact of LGE Granularity Using CMR in End‑Stage Hypertrophic Cardiomyopathy.

Circulation. Cardiovascular imaging·2026
Same author

Drug Adherence After Hospitalisation for Heart Failure: What Have We Learned from a French Survey?

Journal of clinical medicine·2026
Same author

Contemporary surgical outcomes and repair rates in degenerative mitral regurgitation: Real-world insights from the international MITRACURE registry.

The Journal of thoracic and cardiovascular surgery·2026
Same author

The Spectrum of Iatrogenic Valvular Heart Disease.

JACC. Case reports·2026

Related Experiment Video

Updated: May 28, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

[Benfluorex and valvular heart disease].

Christophe Tribouilloy1, Antoine Jeu, Sylvestre Maréchaux

  • 1Département de cardiologie, Inserm, ERI 12, CHU d'Amiens, Amiens, France. Tribouilloy.Christophe@chu-amiens.fr

Presse Medicale (Paris, France : 1983)
|October 11, 2011
PubMed
Summary

Benfluorex, a withdrawn medication, can cause heart valve regurgitation through its metabolite norfenfluramine. While severe cases are rare, aortic and mitral valves are most frequently affected.

Related Experiment Videos

Last Updated: May 28, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Area of Science:

  • Pharmacology
  • Cardiology
  • Toxicology

Context:

  • Benfluorex was marketed for diabetes and obesity.
  • It was withdrawn from the European market in June 2010.
  • Millions exposed in France since 1976, with over 300,000 patients using it at withdrawal.

Purpose:

  • To investigate the link between benfluorex use and valvular heart disease.
  • To assess the prevalence and characteristics of benfluorex-induced valvular regurgitation.

Summary:

  • Benfluorex causes restrictive organic valvular regurgitations via its metabolite, norfenfluramine.
  • Aortic and mitral valves are most commonly affected.
  • Severe regurgitation is rare, estimated at less than 1 per 1000 patient-years.

Impact:

  • Highlights the potential cardiotoxicity of certain pharmaceutical agents.
  • Informs clinical practice regarding patient monitoring for valvular heart disease.
  • Contributes to understanding drug-induced valvular regurgitation epidemiology.